BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3891461)

  • 1. Safety issues relating to the use of mammalian cells as hosts.
    Petricciani JC
    Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment on the carcinogenic potential of hybridoma cell DNA: implications for residual contaminating cellular DNA in biological products.
    Dortant PM; Claassen IJ; van Kreyl CF; van Steenis G; Wester PW
    Biologicals; 1997 Dec; 25(4):381-90. PubMed ID: 9467034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality control of biologicals produced by r-DNA technology.
    Liu DT; Gates FT; Goldman ND
    Dev Biol Stand; 1985; 59():161-6. PubMed ID: 4007274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The control of biological medicinal products produced by recombinant DNA technology.
    Griffiths E
    Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction to the issues: detection of retroviruses and associated risks.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():137-40. PubMed ID: 1478334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell line issues: historical and future perspectives.
    Petricciani JC
    Dev Biol Stand; 1992; 76():5-11. PubMed ID: 1478355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous cell substrate considerations.
    Lubiniecki AS
    Bioprocess Technol; 1990; 10():495-513. PubMed ID: 1370028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of biologicals produced in continuous cell lines.
    Hoffman T; Fratantoni J; Murano G
    Dev Biol Stand; 1989; 70():211-4. PubMed ID: 2668073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety issues related to the use of recombinant DNA-derived cell culture products. I. Cellular components.
    Palladino MA; Levinson AD; Svedersky LP; Obijeski JF
    Dev Biol Stand; 1987; 66():13-22. PubMed ID: 3582742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USDA licensing policy for biologicals produced by R-DNA.
    Espeseth DA; Shibley GP; Joseph PL; van Deusen RA; Whetstone CA
    Dev Biol Stand; 1985; 59():167-73. PubMed ID: 4007275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene stability in mammalian cells and protein consistency.
    Berthold W
    Dev Biol Stand; 1994; 83():67-79. PubMed ID: 7883100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
    Jones AJ; O'Connor JV
    Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cells, science and health.
    Petricciani JC
    Dev Biol Stand; 1989; 70():3-10. PubMed ID: 2668074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A probabilistic model for risk assessment of residual host cell DNA in biological products.
    Yang H; Zhang L; Galinski M
    Vaccine; 2010 Apr; 28(19):3308-11. PubMed ID: 20226252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical considerations and practical concerns regarding the use of continuous cell lines in the production of biologics.
    Petricciani JC; Salk PL; Salk J; Noguchi PD
    Dev Biol Stand; 1981; 50():15-25. PubMed ID: 7341291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Karyology and tumorigenicity testing requirements: past, present and future.
    Petricciani JC; Horaud FN
    Dev Biol Stand; 1998; 93():5-13. PubMed ID: 9737371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.